On Friday, Johnson & Johnson announced that its late-stage study on TREMFYA, used as an induction therapy for adults with moderately to severely active ulcerative colitis, achieved both its primary and secondary objectives. The research displayed outcomes that were both statistically significant and clinically relevant.
HomeFinance NewsJNJ Achieves Primary Goal in Late-Stage Ulcerative Colitis Treatment Trial (NYSE: JNJ)
JNJ Achieves Primary Goal in Late-Stage Ulcerative Colitis Treatment Trial (NYSE: JNJ)
Related stories
Business
Trump Tariffs Stir Chaos; Xi Jinping is Key Threat to Global Economy: Ex-Treasury Official
Trade between China and other countries regarding manufactured goods...
Technology
Webb Telescope Discovers Milky Way Black Hole’s Constant Light Strobing
Researchers have identified that the supermassive black hole at...
Latest News
Musk Demands Federal Employees Document Work or Face Termination: NPR
Federal employees throughout the United States received an email...
Technology
Elon Musk Pressures FBI Agents, Air Traffic Controllers to Answer Email or Resign
Elon Musk has once again influenced official communications within...
Finance News
Experienced fund manager warns of Palantir’s issues
Over the course of three days, Palantir Technologies experienced...
DMN8 Partnershttps://salvonow.com/
DMN8 Partners utilizes a strategy of Cross Channel marketing including local search engine optimization, PPC, messaging and hyper-targeted audiences allow our clients to experience results and ROI that fuel growth and expansion in their operations. There are a lot of digital marketing options across the country but partnering with an agency that understands multiple touches on multiple platforms allows your company’s message to be seen at the perfect time, on the perfect platform, by your perfect prospect. DMN8 Partners has had years of experience growing businesses. Start growing your business today and begin DOMINATE-ing your market.